系统性红斑狼疮B细胞靶向治疗研究概述  

B-cell Targeted Therapy in Systemic Lupus Erythematosus:an Overview

作　　者：沈思钰[1] 朱培元 傅晓东[3] 

机构地区：[1]南京军区南京总医院风湿免疫科,南京210002 [2]南京军区血液中心 [3]复旦大学附属华山医院

出　　处：《药物流行病学杂志》2015年第9期554-557,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：系统性红斑狼疮(SLE)是以多种自身抗体导致不同靶器官损害为特点的自身免疫性疾病,B细胞靶向治疗危重性、难治性病例是目前临床研究的热点和难点,包括抗CD20/CD22阳性B细胞靶向治疗和BAFF拮抗药,其中以利妥昔单抗和贝利单抗临床最常用,且安全有效,其他多数制剂仍在不同阶段的临床试验中。未来研究应在多中心研究的基础上,更专注于理想SLE患者的选择、初始治疗时机的选择、治疗药物的选择以及终止或撤减治疗方法的选择。Nowadays, systemic lupus erythematosus is a challenging autoimmune disease with muhiorgan dysfuncion induced by diverse autoantihodies, and the strategy of B-cell targeted therapy, which including B-cell depletion and inhibition of B-cell activating factor, is not only the hotspot, but also the difficult viewpoint on acute critical and refractory cases in clinic. Moreover, in spite of rituximah and belimumab being efficacy and safety in common, but all the others are being in animal researches and clinical trials. In the future, based on multicenter studies, we should pay more attention in selections of ideal cases, therapeutic drugs, time window of initial treatment and end point of clinical trial.

关 键 词：系统性红斑狼疮 靶向治疗 生物制剂 B细胞活化因子 利妥昔单抗 贝利单抗 EPRATUZUMAB 

分 类 号：R593.241[医药卫生—内科学]